Vaxcyte Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cost of Revenue	-	-	75	23	-
Gross Profit	-	-	-75	-23	-
Selling, General & Admin	129.37	92.9	60.7	39.81	25.26
Research & Development	794.31	476.64	332.34	169.45	78.41
Operating Expenses	923.68	569.55	393.04	209.26	103.67
Operating Income	-923.68	-569.55	-468.04	-232.26	-103.67
Interest Expense	-	-	-	-0	-0.01
Interest & Investment Income	119.72	109.99	62.91	8.36	0.34
Currency Exchange Gain (Loss)	-	-	-	-	1.67
Other Non Operating Income (Expenses)	37.33	-4.38	2.87	0.42	1.59
EBT Excluding Unusual Items	-766.63	-463.93	-402.27	-223.49	-100.08
Gain (Loss) on Sale of Investments	-	-	-	-	0
Pretax Income	-766.63	-463.93	-402.27	-223.49	-100.08
Net Income	-766.63	-463.93	-402.27	-223.49	-100.08
Net Income to Common	-766.63	-463.93	-402.27	-223.49	-100.08
Shares Outstanding (Basic)	136	122	97	65	52
Shares Outstanding (Diluted)	136	122	97	65	52
Shares Change (YoY)	11.55%	25.57%	49.75%	24.95%	75.73%
EPS (Basic)	-5.63	-3.80	-4.14	-3.44	-1.93
EPS (Diluted)	-5.63	-3.80	-4.14	-3.44	-1.93
Free Cash Flow	-712.55	-571.79	-364.67	-176.44	-127.95
Free Cash Flow Per Share	-5.24	-4.69	-3.75	-2.72	-2.46
EBITDA	-907.28	-562.54	-464.89	-229.42	-101.87
D&A For EBITDA	16.4	7	3.16	2.83	1.8
EBIT	-923.68	-569.55	-468.04	-232.26	-103.67

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q